Unique ID issued by UMIN | UMIN000014330 |
---|---|
Receipt number | R000016682 |
Scientific Title | A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer |
Date of disclosure of the study information | 2014/06/23 |
Last modified on | 2017/07/10 15:39:36 |
A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy
in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer
PRINCE
A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy
in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer
PRINCE
Japan |
elderly patients with localy advanced non-small-cell lung cancer
Hematology and clinical oncology |
Malignancy
NO
To determine the maximum-tolerated dose (MTD) and the recommended dose (RD) of radiation and CBDCA+Pemetrexed
Safety
Exploratory
Phase I
To determine the maximum-tolerated dose (MTD)
ORR, PFS, OS
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
CBCDA: AUC4-5, weekly
PEM:500mg/m2, weekly
concurrent TRT: 2Gy/day todal 60Gy
75 | years-old | <= |
Not applicable |
Male and Female
1) Histologically or cytologically confirmed non-sqamous non-small-cell lung cancer with Chemo-naive patients
2) Stage III, without indication for curative resection, with irradiation
3) Patients aged 75- years
4) ECOG performance status 0-1
5) Adequate organ function
6) Excepted to live over 3 months after administration day
7) Written informed consent from the patients
1) squamous cell carcinoma
2) Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray
3) Pleural effusion, pericardial effusion and ascites to need treatment
4) Severe renal function disorder
5) SVC syndrome
6) Brain metastases with neurological symptoms
7) Active double cancer
8) Uncontrollable diabetes mellitus and hypertenson
9) Liver cirrhosis by image findings or laboratory examinations
10) History of severe heart disease (myocardial infarction within 6 months, unstable angina, post-PTCA or CAGB, signs of congestive heart failue, arrythmia with past history of heart failure, etc.)
11) Pregnancy, breast feeding and suspected pregnancy
12) History of grave drug allergic reaction
13) Acute inflammatory disease
14) An agreement is not obtained for support therapy such as transfusion etc
15) Having the bleeding tendency which is clinically apparent
16) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor
12
1st name | |
Middle name | |
Last name | Tomoya Kawaguchi |
Osaka City University Hospital
Chemotherapy center
1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3793
y-naruo@sc4.so-net.ne.jp
1st name | |
Middle name | |
Last name | Naruo Yoshimura |
Osaka City University Hospital
Chemotherapy center
1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
06-6645-3793
y-naruo@sc4.so-net.ne.jp
Osaka Lung Cancer Study Group
None
Self funding
NO
2014 | Year | 06 | Month | 23 | Day |
Unpublished
Terminated
2012 | Year | 01 | Month | 01 | Day |
2013 | Year | 02 | Month | 01 | Day |
2017 | Year | 01 | Month | 31 | Day |
2017 | Year | 03 | Month | 01 | Day |
2017 | Year | 04 | Month | 01 | Day |
2017 | Year | 05 | Month | 01 | Day |
2014 | Year | 06 | Month | 20 | Day |
2017 | Year | 07 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016682
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |